In preclinical studies, short-term treatment with 5-HT4R agonists (RS67333 and others) had anxiolytic and antidepressant properties and mimicked the cellular and molecular responses of AD induced by chronic SSRI administration [199,200]. Here, HTR4 is linked to Alzheimer disease.